Cambridge Healthtech Institute’s 6th Annual
Next-Generation Immunotherapies
In vivo CAR T and the Next Wave of Immune Reprogramming
May 13-14, 2027
The ability to engineer therapeutic immune cells directly inside the body could transform how advanced immunotherapies are developed, manufactured, and delivered. With in vivo CAR T now generating early patient data and record investment from big pharma, Cambridge Healthtech Institute’s 6th Annual Next-Generation Immunotherapies conference will explore the technologies and translational strategies driving the field forward. The program will cover viral vectors, nanoparticles, mRNA, fusogens, and virus-like particles designed to target T cells, NK cells, myeloid cells, and hematopoietic stem cells. Key discussions will address biodistribution, transduction efficiency, genome integration, payload design, immune responses, cellular persistence, safety controls, and mitigation of CRS, neurotoxicity, and off target activity. Additional topics include CAR binder engineering, AI-assisted discovery, and in vivo expression of antibodies, T cell engagers, and multiple payloads. We invite proposals that introduce new data, challenge current thinking, and help define the next generation of programmable immunotherapies.
Coverage will include, but is not limited to:
- In vivo CAR T: Clinical and Translational Updates
- Clinical and translational updates—what are companies seeing in the clinic
- First-in-human lentiviral in vivo CAR T dose-escalation readouts
- Autoimmune and other non-oncology indications
- Transient mRNA versus integrating vectors: durability and redosing
- Translational pharmacology: transduction efficiency and B-cell depletion readouts
- Reducing CRS, neurotoxicity, off-target transduction, and insertional mutagenesis
- Overcoming Limitations of First-Generation in vivo CAR Ts
- Improving cell-selective transduction and targeting
- Overcoming anti-vector immunity for redosing
- Extending CAR persistence and durable responses
- Controlling dosing and off-target toxicity
- Delivery Platforms, Targeting, and Cell Tropism
- Engineered viral envelopes and receptor-retargeted vectors for cell-selective transduction
- Antibody, fragment, and peptide-tag dressing of targeted LNPs
- Fusogen and virus-like particle platforms: on-target specificity benchmarks
- Escaping the liver: lymphoid-directed delivery and biodistribution
- Cell-selective delivery to T cells, NK cells, myeloid cells, or haematopoietic stem cells
- Payload Design, Persistence, and Genome Engineering
- Site-specific in vivo integration of large DNA payloads
- Non-viral genome writing and knock-in platforms, and strategies that avoid double-strand breaks
- Control of expansion and persistence, including synthetic cytokine receptors, inducible systems, and safety switches
- CAR binder affinity, epitope geometry, and synapse dimensions
- Computational and AI-assisted design of targeting ligands and CAR binders, with experimental validation
- Anti-vector and anti-transgene immunity, repeat dosing, durability
- In vivo expression of other biologics, including encoded T cell engagers, antibodies, and multi-payload constructs
The deadline for priority consideration is October 23, 2026.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation:
- To submit a podium presentation, please click here.
- To become a sponsor, click here.
- To present a poster, click here.
- To sign up to attend, click here.